Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
The gross proceeds to the Company from the offering are expected to be approximately $4.3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering
Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering. Shares were down 27% to $3.03 in recent trading after closing at $4.
Vivos Therapeutics (VVOS) stock gains as company receives FDA clearance for its DNA appliance to treat obstructive sleep ...
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, ...
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing ...
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...
U.S. stocks traded higher this morning, with the Nasdaq Composite surging more than 400 points on Thursday. Following the ...
Vivos Therapeutics, Inc. (VVOS) announced on Wednesday that it has obtained 510(k) clearance from the FDA for its DNA oral medical ...
The Nasdaq composite has historically had a high correlation with the S&P 500. The two indexes even share common components, including Apple, Microsoft and Alphabet. Like the S&P 500, the Nasdaq ...
The stage is set for strong weekly wins after Wall Street's expectations for a 0.5% rate cut by the Fed shot up.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback